The World Health Organisation (WHO) estimates the global vaccine wastage currently amounts to 50% for lyophilised and to 25% for liquid vaccines. Arguably one of the biggest contributors to this wastage is disruption in the cold chain supply (Pharmaceutical Technology 2-April-2012).

The definitions and standards that determine the hazard class or division associated with your commodity are found in 49 C.F.R. Part 173. There is a helpful table contained in 49 C.F.R. § 173.2 that provides the location of each hazard class definition in 49 C.F.R. Part 173. These standards are used to determine the classification of your commodity (e-CFR Data, 11-May-2012).

The FDA in its “Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products” recommends for Drug substances intended for storage in a refrigerator to be 5°C ± 3°C, which translates to 2°C – 8°C.

Recent projections from Decade of Vaccines Economics (DoVE) show that by achieving 90% coverage with vaccines for the five leading childhood diseases — including Hib, pneumococcal disease, rotavirus, measles and pertussis — Nigeria could save more than 600,000 lives over the next ten years and add $17 billion to its economy (MarketWatch 12-April-2012).

Abbott Laboratories’ $9-billion arthritis drug Humira is set to take the crown as the world’s top-selling medicine this year (Chicago Tribune 11-April-2012).

FedEx Corp. announced that it signed an agreement to acquire the Polish courier company Opek Sp.z o.o. (Opek), the latest step in its strategy for growth in Europe (3PL News 05-April-2012).

“We are delighted to add these high performance products to our solutions and launch them here in the UK as we did last week in the US,” said David Walsh, CEO DGP Intelsius.  “Not only will this range of products benefit our customers and protect their valuable payloads, but a portion of the proceeds of each sold in the UK and throughout Europe will be donated to our chosen whale and dolphin charity partner, ORCA,” Walsh said.

The ORCA line is a high performance range of solutions that provide superior thermal protection for high value, temperature sensitive payloads.  The entire ORCA range is ATMOS™ (Analytical Thermal Modeling Software) enabled allowing quick risk assessment for the suitability of ORCA on routes around the world.

“The ORCA range also has the option of utilizing our advanced proprietary Thermocline Technology™ (TCT) that allows the ORCA solutions 30 percent extended duration in warm to extreme heat environments and greater controlled pre-conditioning.  Thermochromic labels provide visual verification of readiness for packing,” Walsh said.

The partnership with the ORCA charity aligns the growing global presence of Intelsius and its commitment to environmental stewardship.  “We thank Intelsius for donating a portion of the proceeds from these products to help us,” said Sally Hamilton, ORCA executive director.  Founded in 2000, ORCA is a marine conservation charity dedicated to forging links between people and the sea through the study of whales, dolphins and porpoises.

About Intelsius
Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd, which is headquartered in York, United Kingdom. Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories. With a strong focus on developing environmentally sustainable products and procedures, the company offers solutions to ensure the integrity of customers’ products and samples for better human and animal health worldwide. Intelsius has a growing global presence with manufacturing facilities, distribution hubs and local offices situated throughout the world, including North America, Europe and Asia. For more information, visit www.intelsius.com.

Media Contact:  Tammy Moran (Intelsius) – 317.536.9950 or tammy.moran@intelsius.com

“We are delighted to add these extremely high performing products to our solutions,” said Andrew J. Mills, CEO Intelsius – Americas.  “Not only will these products benefit our customers and protect their valuable payloads, but a portion of the proceeds of each sold in the US will be donated to our partners at the Whale and Dolphin Conservation Society (WDCS) here in Plymouth, Massachusetts,” Mills said during the launch today.

The ORCA line is a high performance range of solutions that provide superior thermal protection for high value, temperature sensitive payloads.  The entire ORCA range is ATMOS™ (Analytical Thermal Modeling Software) enabled allowing quick risk assessment for the suitability of ORCA on routes around the world.

“The ORCA range has the option of utilizing our advanced, proprietary Thermocline Technology™ (TCT) that allows the ORCA solutions 30 percent extended duration in warm to extreme heat environments and greater controlled pre-conditioning.  Thermochromic labels provide visual verification of readiness for packing,” Mills said.

Intelsius continues to grow globally and build a reputation for progressive product development and a commitment to environmental stewardship.  All components of the ORCA range of solutions are designed with the environment in mind.  “These are our most environmentally conscious products to date,” said Mills.

“We applaud Intelsius for recognizing our efforts by donating a portion of the proceeds from the ORCA products,” said Regina Asmutis-Silvia, executive director at WDCS.  “We are proud to lead the way in the efforts to protect whales and dolphins while providing easy to use, technically advanced solutions to the life sciences industry,” Mills said.

About Intelsius
Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd, headquartered in York, United Kingdom. Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories. With a strong focus on developing environmentally sustainable products and procedures, the company offers solutions to ensure the integrity of customers’ products and samples for better human and animal health worldwide. Intelsius has a growing global presence with manufacturing facilities, distribution hubs and local offices situated throughout the world, including North America, Europe and Asia. For more information, visit www.intelsius.com.

www.intelsius.com/orca

Media Contact:  Tammy Moran (Intelsius) – 317.536.9950 or tammy.moran@intelsius.com

Name: Stuart Davidson

Position: Manager of Operations – Americas. I am responsible for operations, logistics and warehouse management.

Why do you work here? To make a positive impact in the life sciences industry.

Favorite product: Xtremotherm, because it has a cool name and provides a unique solution to many of our client’s needs.

Coffee or Tea? Coffee 24/7!!

Do you have a pet? Yes, a cat named Tilly

Favorite Destination: Navajo Reservation in Klagetoh, Arizona

Favorite dish: Ribeye steak with mashed potatoes & gravy and a side salad with Ranch dressing.

Favorite ice cream flavor: Vanilla!

Dangerous or Safe? They call me “Safe Stuart” for a reason!

Would you rather be hot or cold? Cold but next to a warm fire!

When I was a kid I wanted to be… A marine biologist studying sharks

Favorite Quote: Sapientier Si Sincere (Wisely if Sincerely)…Motto of Clan Davidson, a Highland Scottish clan.

Venue: Vancouver, British Columbia, Canada

For more information, click here

Venue: Grand Hyatt Shanghai, China

For more information, click here

Venue: Seaport Hotel, Boston, Massachusetts

For more information, click here 

Venue: TBD, Chicago, Illinois, US

For more information, click here

“South Korea is an important strategic opportunity for Intelsius, our partnership with BioCore as the exclusive distributor of our solutions will allow us to better ensure patient safety in this growing pharma market,” said David Walsh, CEO of Intelsius. “The partnership enables Intelsius to meet the increasing demand for temperature control and regulatory compliant packaging systems for the life science sector in this region.”

“There are more clinical trials going on in South Korea than in any other country in East Asia estimated at more than 3,100,” said Hyung-Sik Choie, president and CEO of BioCore.  “Our partnership with Intelsius will have an immediate impact on the accuracy of those trials and more importantly, it will enhance the safety of the patients participating. “

Experts predict that the growth in cold chain spending over the next three years will be highest in Asia according to the Cold-Chain Biopharma Logistics Sourcebook 2011.

About Intelsius

Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd, which is headquartered in York, United Kingdom.  With a strong focus on developing environmentally sustainable products and procedures, the company offers solutions to ensure the integrity of customers’ products and samples for better human and animal health worldwide. Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories.  Intelsius has manufacturing facilities, distribution hubs and local offices situated throughout the world, including North America, Europe and Asia. For more information, visit www.intelsius.com.

About BioCore

BioCore was established in 2001 as a spin off from Seoul Clinical Laboratories, the largest reference laboratory in Korea since 1983. The drug development support service division (Bio-analysis, eg. PK and PD-Study)  is one of BioCore’s specialized research organizations which utilizes advanced equipment, accumulated analytical ability and more accurate and reliable data complying with GLP standards.  BioCore has the first GLP certification in Korea in the field of toxicokinetics analysis by the KFDA.

Media Contact:

Tammy Moran (Intelsius) – +1 317 536 9950 or tammy.moran@intelsius.com

Venue: Basel, Switzerland

For more information, click here